Shares of Dare Bioscience Inc (NASDAQ:DARE) traded down 7% on Wednesday . The company traded as low as $1.08 and last traded at $1.06. 414,099 shares changed hands during mid-day trading, a decline of 11% from the average session volume of 463,374 shares. The stock had previously closed at $1.14.

Separately, ValuEngine upgraded shares of Dare Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th.

WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at

Dare Bioscience Company Profile

Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with's FREE daily email newsletter.